Review Article

Yang Liu*, Huiqin Hao#, Tiezheng Hou#

Concanavalin A-induced autoimmune hepatitis model in mice: Mechanisms and future outlook

Abstract: The concanavalin A (Con A)-induced liver injury mouse model is a typical animal model focusing on T cell-dependent hepatic damage in the field of autoimmune hepatitis (AIH). However, the underlying mechanism of hepatic dysfunction due to cell activation or signaling pathways triggered by Con A has not been fully clarified. Therefore, the controversy on this model remains in the academic community. In this article, we first summarized the merit and demerit of this contentious model from the perspectives of cell dysfunction, microcirculation disturbance, involved signaling pathways, as well as the properties of Con A. Then, we summed up the scientific implications of the model in elucidating the pathogenesis of AIH, and the shortcomings of this model were also summarized to elucidate the pathogenesis and application prospect of this classical liver injury mouse model in the study of AIH.

Keywords: autoimmune hepatitis, concanavalin A, experimental animal models, inflammation, pathogenesis

1 Introduction

Autoimmune hepatitis (AIH), originally named “active chronic and lupoid hepatitis” by Ian R. Mackay and F. Macfarlane Burnet in 1963, is a type of chronic progressive inflammation of liver parenchyma mediated by autoimmune response [1]. It is closely related to the abnormal proliferation and activation of T lymphocytes and is distinguished by interfacial hepatitis in histology and by elevation of immunoglobulin G level and presence of autoantibodies in serology. Moreover, it eventually may cause fibrosis and cirrhosis if the inflammation process cannot be controlled [2]. AIH occurs globally in all ages and ethnicities with a strong female predominance [3], and its incidence and prevalence are still increasing in recent years [4,5]. Establishing an ideal experimental animal model to mimic the progress of human AIH in the laboratory is thought to be helpful in better studying the specific pathogenesis of this disorder and exploring more effective clinical treatment methods. Many researchers have devoted themselves to the evolution of animal models related to AIH since the early 1970s [6]. Notwithstanding a variety of animal models that have been applied to the study on the etiopathogenesis of AIH in different phases, the concanavalin A (Con A)-induced liver injury mouse model is regarded as the most important one [7,8]. It was successfully established in 1992 by Tiegs G [9] and was commonly used in such research fields from the 1990s to 2020s [10–13]. Not only this model is easy, convenient, inexpensive, and repeatable to establish [14,15] but also its histological features (including peripoortal and intralobular lymphocytes infiltrates as well as interface hepatitis) and serological changes (i.e., high levels of transaminase) are similar to human AIH patients [16]. However, this widely applied model is still debatable with the deepening of research on the mechanisms causing liver injury [17]. An in-depth summary of the controversies over this model, together with its pros and cons, will be conducive to illustrate its status and meet the future challenge in the study of AIH.
2 Multiple populations of cells participating in the hepatic injury in this model

Initially, the Con A-induced liver injury mouse model was regarded as a well-established CD4+ T helper cell (Th) activated model focusing merely on the dysfunctional Th involved in the pathogenesis of AIH [9]. However, as the research moved along, it was revealed that, except for Th, a variety of other immunocytes and hepatic nonparenchymal cells were related to the development of hepatocellular injury, including cytotoxic CD8+ T lymphocyte (CTL) [18], natural killer T cell (NKT) [19,20], neutrophil [21], kuffer cell (KC) [22,23], and sinusoid endothelial cell (SEC) [24,25]. As shown in Figure 1, Con A is capable of attaching not only to the MHC class II, MR, and ICAM-1. Th0 cell differentiated into Th1, Th2, Th17, and Treg by the recognition of MHC class II-Con A complex via TCR, and Th1 and Th17 induced the hepatocyte necrosis and apoptosis by secreting TNF-α, IFN-γ, IL-17, and IL-22, while Th2 and Treg would induce tolerance toward Con A by secreting IL-10 or expressing CTLA. Th0 could also migrate to the inflamed tissue by adhering to CXCLs via CXCR3. The NKT directly induced the death of hepatocytes or SECs by expressing TNF-α and IFN-γ after combining with this lectin through TCR. The MRs, located on the surface of macrophages and neutrophils, contain multiple CTLD, and the N-acetylglucosamine of Con A can combine to the MRs to induce the receptor-mediated endocytosis and phagocytosis to maintain the stability of the internal environment. At the same time, Con A also can lead to the activation of macrophages and neutrophils via MRs, to increase the release of superoxide anions and induce the synthesis of cytokines (including TNF-α, IFN-γ, IL-1β, MIP-2, and ROS). Con A promoted the expression of β2-integrin on neutrophils, which was essential for neutrophil recruitment. The attachment of SECs to Con via MR, MHC class II, and ICAM-1 could give rise to their death, facilitating the adhesion of Con A to KCs. CTLs would activate by the Con A-mediated expression of TNF-α and IFN-γ and infiltrate to the necrotic area by recognizing MHC class I expressed on the surface of damaged hepatocytes, which is absent from the normal liver tissue. Both CTLs and NKTs contributed to the apoptosis of hepatic cells via the Fas/FasL pathway.
in vivo experiments (the data have not been reported). The 
MRs, which are located on the macrophage surface, con-
tain multiple C-type lectin-like domains (CTLD), and 
the N-acetylglucosamine of Con A can combine to the 
MRs to induce receptor-mediated endocytosis and pha-
gocytosis to maintain the stability of the internal envi-
ronment. At the same time, Con A also can lead to the 
activation of macrophages via MRs, to increase the release 
of superoxide anions and induce the synthesis of cyto-
kines. These cells participate in hepatic damage in direct 
or indirect ways. For example, Th0 cells will be activated 
by recognizing the MHC class II-Con A complex via T cell 
receptor (TCR) and differentiated into Th1, Th2, Th17, and 
regulatory T cell (Treg). Th1 and Th17 are characterized by 
secreting tumor necrosis factor (TNF)-α, interferon (IFN)-γ, 
and interleukins (IL)-17, IL-22 to induce hepatocyte necrosis 
and apoptosis [30]. At the same time, Th2 and Treg are 
featured by secreting IL-10 and expressing cytotoxic T lympho-
cyte antigen (CTLA)-4, which are supposed to induce 
tolerance toward Con A [31]. Th0 can also migrate to the inflamed tissue by the recognition of CXC chemokine ligands 
(CXCLs) expressed on the cytomembrane of injured hepatocytes via CXC chemokine receptor motif 3 (CXCXR3) [32,33]. Although CTL does not have an 
immediate relationship with Con A, the activation of 
CTL is deemed to be induced by the Con A-mediated expres-
sion of TNF-α and IFN-γ, and CTLs will infiltrate the necrotic 
area by the recognition of MHC class I expressed on the 
surface of damaged liver cells, which is absent from the 
healthy liver tissue [34]. That is why CD4+ T cells are 
reported to be particularly numerous in perportal areas, 
while CTLs constitute the major cell type in the area of 
interface lymphocytic infiltration [35], and the ratio of 
CD4+ T cell to CTL in Con A-induced AIH mice model is 
higher than in other liver diseases [36,37]. Both CTLs and 
NKTs contribute to the apoposis of hepatic cells via the 
Fas/FasL pathway [34]. Unlike T cells, the KC, neutrophil, 
and NKT are able to directly induce the death of hepatocytes 
or SECs by expressing TNF-α, IFN-γ, IL-1β, macrophage 
inflammatory protein (MIP)-2, and reactive oxygen species 
(ROS) after being activated by this lectin through TCR or MR 
[19]. Con A increases the expression of β 2-integrin on neu-
rophils as well, and the recruitment of neutrophils is a 
β 2-integrin-dependent process [38]. Moreover, SECs are 
capable of binding to Con A at 4 h after intravenous injec-
tion via MR, MHC II, and intracellular adhesion molecule 
(ICAM)-1 on its surface. This attachment will lead to the 
breakdown of the SEC’s membrane and bleb formation 
and eventually give rise to their detachment, facilitating 
the adhesion of Con A to KCs [14]. So numerous cells are 
involved in constructing this model that it is like getting 

blood from a stone to improve the hepatic injury by interf-
ering with the abnormal activation of a particular type of 
cell. It is probably the main reason why this model’s etio-
pathogenesis is still obscure, and no appropriate and 
acknowledged in vitro model was able to identically imi-
tate the pathogenetic process of this hepatitis model, 
unlike other autoimmune diseases, such as rheumatoid arthritis [39]. 

However, this model’s “unexpected” multicellular 
participation mechanism opens a gate to closely mirror 
most of the pathogenic properties in AIH human patients 
[40]. On the other hand, it is because of the abundant “unintended” hepatic nonparenchymal cells (such as SECs and KCs) involved in the establishment of this model that the 
binding of Con A to the liver seemed to be very specific [41]. 
It has been demonstrated that the organotropism of FITC-
labeled Con A for the liver was remarkable, while fluores-
cence in other tissues was so weak that it was undetectable, 
including the lung (the organ that Con A passed first after 
intravenous injection) and kidney (the organ has the largest 
blood flow). The selective organ damage induced by Con A 
results from the MRs significantly expressed on the SECs and 
KCs, and Con A-inducible lesions were absent in macro-
phage-depleted animals [26,42]. Therefore, although it is 
not consistent with the original purpose of establishing 
this model, it is still widely used now.

3 Genetic background and gender 
preference of animal deserving to 
take into consideration 

As more and more experiments were carried out in dif-
f erent mouse strains, including C57BL/6 [43], C3H [44], 
BALB/c [45], NMRI [46], and FVB/N [47], it was demon-
strated that the dosage of Con A needed to trigger hepatic 
injury varied significantly according to the genetic back-
ground of mice. Generally, Th1-biased C57BL/6 and C3H 
mice are more susceptible to Con A and normally require 
lower doses of Con A only around 15–20 mg/kg body weight, 
while mice with Th2-biased immune response, such as 
BALB/c or NMRI mice, commonly need higher doses of 
this lectin up to >30 mg/kg body weight [48]. Therefore, 
the genetic background of animals needs to be considered 
when establishing this hepatitis model, due to that Con A is 
prone to induce a Th1-biased immune response. 

Though AIH shows the female preponderance with a 
female-to-male ratio of 4:1 [49], it is preferable to implement 
the Con A-induced liver injury experiment exclusively using
male mice in order to minimize the number of animals required for reaching statistically significant results. The prime reason is that the immune response induced by Con A is considerably dependent on the hormonal state of the animal, and the female mice are more sensitive to Con A than male ones and show a greater variation in the degree of liver injury and level of cytokine production [50]. Nevertheless, it is helpful to study the gender-related differences in the development of human AIH patients by taking advantage of the gender preference of the model.

4 Intricate signal transduction pathways involved in the pathogenesis of this model

Along with the deepening of the research, a complicated network of signal transduction pathways referring to provoking or exacerbating the impairment of liver function in this model was gradually disclosed, including “Toll like receptor (TLR) signaling pathway” [51,52], “MAPK signaling pathway” [53], “PI3K/Akt signaling pathway” [54,55], “Ferroptosis” [56], “Notch signaling pathway” [57], “Wnt signaling pathway” [58,59], “Endocytosis” [60], and so on. The data in one of our earlier experiments also showed that the differentially expressed mRNAs (DEMs) filtered out by microarray with this model were significantly enriched in these pathways [61]. Furthermore, many new therapeutic antibodies, drugs, or monomers targeting these validated pathways have been increasingly developed to attenuate hepatic damage. For instance, fucosterol and nobiletin were confirmed to alleviate the acute liver lesion through regulating the “MAPK signaling pathway” [62,63], ghrelin and salidroside were deemed to improve liver function in this model via “PI3K/Akt signaling pathway” [64,65], while Hu23C3 (a humanized murine monoclonal antibody against human osteopontin) and CpG-containing oligodeoxynucleotides were supposed to mitigate the hepatic injury and enhance the survival rate of mice by interfering with “NF-κB signaling pathway” [66,67]. Nevertheless, the complexity of the interaction of these pathways exceeded the expectation so that the nosogenesis of this model became more and more incomprehensible, and there is still no specific drug that is able to thoroughly improve the inflammatory damage to liver.

According to the published literature, we found that NF-κB is a vital hub gene associated with the setting up of this hepatitis model because this transcription factor is likely to be the intersection of numerous signal transduction pathways [68–70]. Parts of the pathways probably related to NF-κB were exhibited in Figure 2. NF-κB was initially reported as a B-cell-specific transcription factor that binds the κB site in the Igκ light chain enhancer [71]. It can be activated by a variety of inflammatory signals. Pro-inflammatory cytokines and pathogen-associated molecular patterns, working through different receptors, including TNF receptor (TNFR), TLR, and IL-1 receptor (IL-1R) superfamilies, cause the activation of inhibitory κB kinase (IKK) complex and translocation of NF-κB dimers from the cytoplasm to the nucleus, resulting in synergistic expression of multiple inflammatory and innate immune genes eventually. The IL-1β, IL-6, and TNF-α activate NF-κB. Meanwhile, expressions of these pro-inflammatory cytokines are also modulated in response to the activation of NF-κB, thus forming an amplifying feed-forward loop [72,73]. Therefore, drug development targeting this hub gene may be more promising.

5 Acute inflammation process and no detectable autoantibodies

Admittedly, AIH starts with an episode of acute hepatitis in some cases. However, most of the patients are typical of progressive chronic hepatitis, and hepatic fibrosis or cirrhosis will ultimately be caused if the autoimmune process is not well-controlled [2,74]. Whereas Con A-induced liver inflammation is typical acute hepatitis. The hepatocyte apoptosis and elevated transaminase levels in serum can be detected as early as 5 h after administration, and it is sufficient to investigate the inflammatory phenotype at 8–12 h after receiving an injection [48]. In addition, it is not feasible to perform long-term follow-up experiments or mimic a chronic inflammatory process through a repetitive application of Con A because mice are able to develop protective immune tolerance against hepatitis induced by this lectin, and IL-10 plays an important role in this course [31]. As time goes by, once Con A is metabolized, the self-repair of the liver will initiate, which can be manifested by declined transaminase levels in serology and hepatocyte regeneration in histology. At last, the pathological process of AIH terminates, and liver damage will be restored. Con A-induced liver damage is transient and unsustainable, so it is not suitable for exploring the pathogenic mechanism of chronic hepatitis.

The presence of specific antibodies to particular liver autoantigens in serum is regarded as one of the core diagnostic criteria of AIH [75,76], including anti-nuclear antibody, anti-smooth muscle antibody, anti-liver-kidney
microsomal antibody, and anti-liver cytosol type 1 antibody [77,78]. Nonetheless, no circulating autoantibody is produced in the Con A-induced liver injury mice model. For one thing, it is a lack of requirement for antigen specificity in this model, owing to that Con A is the unique agent to activate and recruit T lymphocytes into the liver tissue [9]. For another, the low levels of IL-4, IL-10, and IL-13 also contribute to the shortage of autoimmune antibodies. Because these cytokines, which are mainly secreted by Th2 cells, are essential for B cells maturation to plasma cells to secrete autoantibodies [2,79]. Under the healthy condition, the ratio of Th1 to Th2 is in dynamic equilibrium and controlled by the transcription factor T-bet and GATA-binding factor type 3 (GATA3) [80]. Con A promotes the skewing of Th1 by increasing the expression of T-bet and suppressing the differentiation of Th2 via decreasing the expression of GATA3 [81]. As mentioned before, the Th1-biased C57BL/6 and C3H mice are most susceptible to Con A-induced liver injury. In contrast, mice with a Th2-biased immune response, such as BALB/c or NMRI mice, require

**Figure 2:** The signal transduction pathways targeting NF-κB are involved in building the Con A-induced AIH mouse model. Numerous inflammatory signals (such as IL-1β, IL-6, TNF-α, and some other pro-inflammatory cytokines) could give rise to the activation of IkKs and translocation of NF-κB dimers from the cytoplasm to the nucleus, through multiple signal transduction pathways, including "TLR signaling pathway", "MAPK signaling pathway", and "PI3K/Akt signaling pathway". The nuclear translocation of NF-κB resulted in the synergistic expression of multiple inflammatory and innate immune genes eventually, involving IL-1β, IL-6, and TNF-α as well. Thus, IL-1β, IL-6, TNF-α, and NF-κB formed an amplifying feed-forward loop. (1) PI3K/Akt signaling pathway, (2) TLR-2 and 4 signaling pathway, (3) TNF-α signaling pathway, and (4) MAPK signaling pathway.
higher doses of Con A. Without the participation of B cells and no generation of autoantibodies are deemed to be the biggest obstacle in translating this model into the investigation on human AIH.

6 The side-effect for Con A as a lectin

6.1 Microcirculation disturbance

As previously mentioned, the original intention on the foundation of this hepatitis mouse model was to investigate the T cell-dependent mechanisms of liver injury. Nevertheless, as a lectin with coagulation activity, if administered intravenously, Con A will first cause a significant decrease in blood flow in the hepatic sinusoid rather than hepatocellular injury [82]. After that, SECs, KCs, and abnormally activated T cells will work in coordination to lead to the formation of numerous microthrombi and bring about the necrosis of hepatocytes [83]. The microcirculation disturbance mechanism induced by Con A was visualized in Figure 3, which would explain why it is different to fully interrupt the immunologic injury induced by Con A only depending on the immunosuppressor, and heparin, an important anti-clotting agent with no immunomodulatory function, has significant protective effects on hepatic injury induced by this lectin without reducing the production of IFN-γ and TNF-α [84]. Hence, microcirculation disturbances induced by Con A is an unintended mechanism on the liver damage, and to some extent, it will interfere with the judgment on the outcome of new drugs associated with the immunologic mechanism.

6.2 Environmental sensitivity

Since Con A is a water-soluble tetrameric protein complex purified from the crude extract of Canavalia ensiformis seeds, its biological activity shows batch-dependent variations [85]. It is sensitive to environmental decay once

Figure 3: The microcirculation disturbance mechanism related to the foundation of Con A-induced AIH mouse model. Con A first caused a significant decrease in blood flow in the hepatic sinusoid after being administrated. Thereafter, abnormally activated T cells immediately produce a large amount of IFN-γ and TNF-α, and then the STAT1 signaling pathway is activated to promote the SECs and KCs to synergistically express tissue factor (TF). TF facilitated the fibrinogen agglutinating into fibrin clots as a starting factor of coagulation reaction. TNF-α triggered the production of plasminogen activator inhibitor type 1 to inhibit the anticoagulant pathway by suppressing the degradation of fibrin clots into fibrinogen degradation product. SECs and KCs could also express TF after adhering to Con A directly. All of them worked together to result in hypercoagulation and form numerous microthrombi, which would eventually contribute to the necrosis of hepatocytes. The anti-clotting agent, such as heparin, has significant protective effects on the hepatic injury induced by lectin through inhibiting the clotting activity.
not stored under protected conditions, so repeated freeze-thaw cycles should be avoided to circumvent protein degradation [86]. Meanwhile, serving as the sole inducer in this model, the levels of transaminase and pro-inflammatory cytokine, considered as the valid index of the severity of the liver injury, change in a Con A-dose-dependent manner [87]. If the intake of Con A is too high, liver damage will be irreversible so that some mice will have the symptom of acute liver failures such as encephalopathy or ascites and die in a short time. Therefore, the dose of Con A needed to induce liver injury has to be tested for each batch before an experimental series, and it is necessary to titrate the Con A dosage accurately to minimize the number of animals succumbing to hypohepatia. Ordinarily, 5–10 mg/kg dose of Con A for 18 h are safe for mice, while 15, 20, and 25 mg/kg will induce 20, 40, and 60% death of mice, respectively [88].

### 7 Application prospect and possible improvements

Although there are some deficiencies in the Con A-induced liver injury mouse model to completely mimic the pathogenesis and pathological process of AIH in human patients, it is still a well-established and easy to replicate animal model focusing on T cell-mediated hepatic damage (Table 1). In addition, this model is also of great significance to develop new therapeutic drugs or other treatment measures just targeting T cell activation. To cover the model shortage, the following improvements could be taken into account to implement.

First, high-throughput detection techniques on screening the differentially expressed genes (involving the coding RNA and non-coding RNA) can be applied to this model, just like the research we are doing, to further explain the interaction between signal transduction pathways [61,89,90]. In particular, much more attention should be paid to the differentially expressed genes enriched in signaling pathways associated with T cell activation and NF-κB transcription.

Second, some kinds of in vitro models could be considered to verify the experimental results obtained from this Con A related in vivo model. For example, the Con A-mediated macrophage activation model is conducive to further interpret the role of KCs in the pathogenesis of AIH, which are primarily found in mice experiments [91,92]. Due to the dominant role in the development of AIH played by Th1-biased immune response, the Th1 cell in vitro model established in accordance with the Th1-skewing condition will serve the purpose of investigating the effects of Th1 cells on liver injury [93,94].

Third, it seems that the utilization of transgenic animals will make up its defects to some extent and is helpful in the discovery of novel biomarkers and potentially new therapeutic targets [95–99]. Furthermore, in view of the agglutination activity of Con A as a lectin, certain kinds of anticoagulant drugs, such as heparin, can be considered to prophylactically administrate to as far as possible mitigate the effects of microcirculation disturbance on the experiments principally aiming at exploring the mechanism of immune disorders.

To sum up, parts of the mechanisms of hepatotoxicity by Con A have been revealed in this article, i.e., Con A, as a kind of lectin, can lead to the activation of macrophage and neutrophil via MRs to increase the release of superoxide anions and induce the synthesis of cytokines, as well as activate Th0 cell via TCR by forming the MHC class II-Con A complex. Con A can also promote the formation of hypercoagulation and form numerous microthrombi in the hepatic sinusoid, which would eventually contribute to hepatocyte necrosis. Moreover, numerous inflammatory signals can be activated after the administration of Con A. Therefore, there is a reasonable prospect that, with continuous improvement and optimization, the research related to the Con A-induced liver injury mouse model will achieve a significant breakthrough and innovation, which will be conducive to a further study in the field of AIH in the future.

**Funding information:** This study was funded by Basic applied study of Shanxi Province (Grant Number:
201901D111333, Grant Recipient: Yang Liu); Innovative projects of Universities in Shanxi Province (Grant Number: 2020LO423, Grant Recipient: Yang Liu); Science and Technology Innovation Program of Shanxi University of Chinese Medicine (Grant Number: 2020PY-JC-07, Grant Recipient: Yang Liu); The Basic Laboratory of Integrated Traditional Chinese and Western Medicine, Shanxi University of Chinese Medicine.

**Author contributions:** Yang Liu wrote the original draft. Tiezheng Hou and Huiqin Hao conceived and designed the project, reviewed, and edited the article.

**Conflict of interest:** Authors state no conflict of interest.

**Data availability statement:** The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

**References**

[1] Gershwin ME, Krawitt EL. Autoimmune hepatitis: 50 years of (slow) progress. Hepatology. 2014;59(3):754–6.

[2] Mielni-Vergani G, Vergani D, Czaja AJ, Manns MP, Krawitt EL, Vierling JM, et al. Autoimmune hepatitis. Nat Rev Dis Primers. 2018;4:18017.

[3] Schwinge D, Schramm C. Sex-related factors in autoimmune liver diseases. Semin Immunopathol. 2019;41(2):165–75.

[4] Valgeirsson KB, Breinson JP, Björnsson ES. Increased incidence of autoimmune hepatitis is associated with wider use of biological drugs. Liver Int: Off J Int Assoc Study Liver. 2019;39(12):2341–9.

[5] Sharma R, Verna EC, Söderling J, Roelstrate B, Hagström H, Jonas F, et al. Increased mortality risk in autoimmune hepatitis: a nationwide population-based cohort study with histopathology. Clin Gastroenterol Hepatol. 2020;S1542–3565(20):31395.

[6] Büschenfelde KH, Kössling FK, Miescher PA. Experimental chronic active hepatitis in rabbits following immunization with human liver proteins. Clin Exp Immunol. 1972;11:1.

[7] Czaja AJ. Animal models of autoimmune hepatitis. Expert Rev Gastroenterol Hepatol. 2010;4(4):429–43.

[8] El-Kashf DH, Abdelrahman RS. Montelukast ameliorates Concanavalin A-induced autoimmune hepatitis in mice via inhibiting TNF-α/JNK signaling pathway. Toxicol Appl Pharmacol. 2020;393:114931.

[9] Tieg S, Hentschel J, Wendel AA. T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest. 1992;90(1):196–203.

[10] Nishikage T, Seki S, Toyabe S, Abo T, Kagaya Y, Iwai T, et al. Inhibition of concanavalin A-induced hepatic injury of mice by bacterial lipopolysaccharide via the induction of IL-6 and the subsequent reduction of IL-4: the cytokine milieu of concanavalin A hepatitis. J Hepatol. 1999;31(1):18–26.

[11] Hoffmann F, Sass G, Zillies J, Zahler S, Tieg S, Hartkorn A, et al. A novel technique for selective NF-kappaB inhibition in Kupffer cells: contrary effects in fulminant hepatitis and ischaemia-reperfusion. Gut. 2009;58(12):1670–8.

[12] Xu C, Zhang C, Ji J, Wang C, Yang J, Geng B, et al. CD36 deficiency attenuates immune-mediated hepatitis in mice by modulating the proapoptotic effects of CXC chemokine ligand 10. Hepatology. 2018;67(5):1943–55.

[13] Yan B, Ai Y, Sun Q, Ma Y, Cao Y, Wang J, et al. Membrane damage during ferroptosis is caused by oxidation of phospholipids catalyzed by the oxidoreductases POR and CYB5R1. Mol Cell. 2021;81(2):355–69.

[14] Wang H-X, Liu M, Weng S-Y, Li J-J, Xie C, He H-L, et al. Immune mechanisms of Concanavalin A model of autoimmune hepatitis. World J Gastroenterol. 2012;18(2):119–25.

[15] Christen U, Hintermann E. Immunopathogenic mechanisms of autoimmune hepatitis: how much do we know from animal models? Int J Mol Sci. 2016;17(12):2007.

[16] Jaeckel E, Hardtke-Wolenski M, Fischer K. The benefit of animal models for autoimmune hepatitis. Best Pract Res Clin Gastroenterol. 2011;25(6):643–51.

[17] Wang H, Yan W, Feng Z, Gao Y, Zhang L, Feng X, et al. Plasma proteomic analysis of autoimmune hepatitis in an improved AIH mouse model. J Transl Med. 2020;18(1):3.

[18] Salas JR, Chen BY, Wong A, Cheng D, Van Arnsm JS, Witte ON, et al. 18F-FAC PET selectively images liver-infiltrating CD4 and CD8 T cells in a mouse model of autoimmune hepatitis. J Nucl Med. 2018;59(10):1616–23.

[19] Strasser A, Jost PI, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity. 2009;30(2):180–92.

[20] Takeda K, Hayakawa Y, Van Kaer L, Matsuda H, Yagita H, Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci USA. 2000;97(10):5498–503.

[21] Bonder CS, Ajueobor MN, Zbytnuk LD, Kubes P, Swain MG. Essential role for neutrophil recruitment to the liver in concanaavalin A-induced hepatitis. J Immunol. 2004;172(1):45–53.

[22] Hatano M, Sasaki S, Ohata S, Shiratsuchi Y, Yamazaki T, Nagata K, et al. Effects of Kupffer cell-depletion on Concanavalin A-induced hepatitis. Cell Immunol. 2008;251(1):25–30.

[23] Yang Y, Yan M, Zhang H, Wang X. Substance P participates in immune-mediated hepatic injury induced by concanaavalin A in mice and stimulates cytokine synthesis in Kupffer cells. Exp Ther Med. 2013;6(2):459–64.

[24] Magnusson S, Berg T. Extremely rapid endocytosis mediated by the mannose receptor of sinusoidal endothelial rat liver cells. Biochem J. 1989;257(3):651–6.

[25] Knoile PA, Gerken G, Loser E, Dienes HP, Gantner F, Tiegs G, et al. Role of sinusoidal endothelial cells of the liver in concanaavalin A-induced hepatic injury in mice. Hepatology. 1996;24(4):824–9.

[26] Tsui T-Y, Obed A, Stu Y-T, Yet S-F, Prantl L, Schlitt HJ, et al. Carbon monoxide inhalation rescues mice from fulminant hepatitis through improving hepatic energy metabolism. Shock. 2007;27(2):165–71.

[27] Takahashi K, Donovan MJ, Rogers RA, Ezekowitz RA. Distribution of murine mannose receptor expression from early embryogenesis through to adulthood. Cell Tissue Res. 1998;292(2):311–23.
[28] Linehan SA. The mannose receptor is expressed by subsets of APC in non-lymphoid organs. BMC Immunol. 2005;6:4.

[29] Weinbaum DL, Sullivan JA, Mandell GL. Receptors for concanavalin A cluster at the front of polarized neutrophils. Nature. 1980;286(5774):725–7.

[30] Webb GJ, Hirschfield GM, Krawitt EL, Gershwin ME. Cellular and molecular mechanisms of autoimmune hepatitis. Annu Rev Pathol. 2018;13:247–92.

[31] Erhardt A, Biburger M, Papadopoulos T, Tieg S. IL-30, regulatory T cells, and Kupffer cells mediate tolerance in concanavalin A-induced liver injury in mice. Hepatology. 2007;45(2):475–85.

[32] Hashimoto E, Lindor KD, Homburger HA, Dickson ER, Czaja AJ, Wiesner RH, et al. Immunohistochemical characterization of hepatic lymphocytes in primary biliary cirrhosis in comparison with primary sclerosing cholangitis and autoimmune chronic active hepatitis. Mayo Clin Proc. 1993;68(11):1049–55.

[33] Wen L, Peakman M, Lobo-Yeo A, McFarlane BM, Mowat AP, Mieli-Vergani G, et al. T-cell-directed hepatocyte damage in autoimmune chronic active hepatitis. Lancet. 1990;336(8730):1527–30.

[34] Ge W, Gao Y, Zhao Y, Yang Y, Sun Q, Yang X, et al. Decreased T-cell mediated hepatic injury in concanavalin A-treated PLRP2-deficient mice. Int Immunopharmacol. 2020;85:106604.

[35] De Biasio MB, Periolo N, Avagnina A, Garcia de Dávila MT, Ciocca M, Goñi J, et al. Liver infiltrating mononuclear cells in children with type 1 autoimmune hepatitis. J Clin Pathol. 2006;59(4):417–23.

[36] Löhr HF, Schlaak JF, Gerken G, Fleischer B, Dienes HP, Meyer, et al. Phenotypical analysis and cytokine release of liver-infiltrating and peripheral blood T lymphocytes from patients with chronic hepatitis of different etiology. Liver. 1994;14(3):161–6.

[37] Senaldi G, Portmann B, Mowat AP, Mieli-Vergani G, Vergani D. Immunohistochemical features of the portal tract mononuclear cell infiltrate in chronic aggressive hepatitis. Arch Dis Child. 1992;67(12):1447–53.

[38] Gujral JS, Farhood A, Bajt ML, Jaeschke H. Neutrophils aggravate acute liver injury during obstructive cholestasis in bile duct-ligated mice. Hepatology. 2003;38(2):355–63.

[39] Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev. 2010;233(1):233–55.

[40] Floreni A, Restrepo-Jiménez P, Secchi MF, De Martin S, Leung PSC, Krawitt E, et al. Etiopathogenesis of autoimmune hepatitis. J Autoimmun. 2018;95:133–43.

[41] Gantner F, Leist M, Lohe AW, Germann PG, Tieg S. Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumour necrosis factor. Hepatology. 1995;21(1):190–8.

[42] Tsutsui H, Nishiguchi S. Importance of Kupffer cells in the development of acute liver injuries in mice. Int J Mol Sci. 2014;15(5):7711–30.

[43] Massagué A, Perez-Del-Pulgar S, Engel P, Serratosa J, Bosch J, Pizcueta P. Concanavalin A-induced liver injury is severely impaired in mice deficient in P-selectin. J Leukoc Biol. 2002;72(2):262–70.

[44] Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, et al. Lethal effect of the anti-Fas antibody in mice. Nature. 1993;364(6440):806–9.

[45] Trautwein C, Rakemann T, Malek NP, Plümpe J, Tieg S, Manns MP. Concanavalin A-induced liver injury triggers hepatocyte proliferation. J Clin Invest. 1998;101(9):1960–9.

[46] Tieg S, Wolter M, Wendel A. Tumor necrosis factor is a terminal mediator in galactosamine/endotoxin-induced hepatitis in mice. Biochem Pharmacol. 1989;38(4):627–31.

[47] Tomiyama C, Watanabe H, Izutsu Y, Watanabe M, Abo T. Suppressive role of hepatic dendritic cells in concanavalin A-induced hepatitis. Clin Exp Immunol. 2011;166(2):258–68.

[48] Heymann F, Hamesch K, Weiskirchen R, Tacke F. The concanavalin A model of acute hepatitis in mice. Lab Anim. 2015;49(1 Suppl):12–20.

[49] Gatselis NK, Zachou K, Koukoulis GK, Dalekos GN. Autoimmune hepatitis, one disease with many faces: etiopathogenic, clinic-laboratory and histological characteristics. World J Gastroenterol. 2015;21(1):60–83.

[50] Takamoto S, Nakamura K, Yoneda M, Makino I. Gender-related differences in concanavalin A-induced liver injury and cytokine production in mice. Hepatol Res. 2003;27(3):221–9.

[51] Chi G, Feng XX, Ru YX, Xiong T, Gao Y, Wang H, et al. TLR2/4 ligand-amplified liver inflammation promotes initiation of autoimmune hepatitis due to sustained IL-6/IL-12/IL-4/IL-25 expression. Mol Immunol. 2018;59:171–81.

[52] Mo R, Feng XX, Wu YN, Wang H, He YP, Sun HH, et al. Hepatocytes paradoxically affect intrahepatic IFN-gamma production in autoimmune hepatitis due to Gal-9 expression and TLR2/4 ligand release. Mol Immunol. 2020;123:106–15.

[53] Zhang M, Li Q, Zhou C, Zhao Y, Li X, Zhang Y. Demethyleneberberine attenuates concanavalin A-induced autoimmune hepatitis in mice through inhibition of NF-κB and MAPK signaling. Int Immunopharmacol. 2020;80:106137.

[54] Xu S, Wu L, Zhang Q, Feng J, Li S, Li J, et al. Pretreatment with propylene glycol alginic acid sodium salt ameliorated concanavalin A-induced liver injury by regulating the PI3K/Akt pathway in mice. Life Sci. 2017;185:103–13.

[55] Fan X, Men R, Wang H, Shen M, Wang T, Ye T, et al. Methylprednisolone decreases mitochondria-mediated apoptosis and autophagy dysfunction in hepatocytes of experimental autoimmune hepatitis model via the Akt/mTOR signaling. Front Pharmacol. 2019;10:1189.

[56] Zeng T, Deng G, Zhong W, Gao Z, Ma S, Mo C, et al. Indoleamine 2, 3-dioxygenase 1 enhances hepatocytes ferroptosis in acute immune hepatitis associated with excess nitrosative stress. Free Radic Biol Med. 2020;152:668–79.

[57] Hao X, Li Y, Wang J, Ma J, Zhao S, Ye X, et al. Deficient O-GlcNAc glycosylation impairs regulatory T cell differentiation and notch signaling in autoimmune hepatitis. Front Immunol. 2018;9:2089.

[58] Tan K, Xie X, Shi W, Miao L, Dong X, Yang W, et al. Deficiency of canonical Wnt/β-catenin signalling in hepatic dendritic cells triggers autoimmune hepatitis. Liver Int: Off J Int Assoc Stud Liver. 2020;40(1):131–40.

[59] Raich-Regué D, Glancy M, Thomson AW. Regulatory dendritic cell therapy: from rodents to clinical application. Immunol Lett. 2014;161(2):216–21.

[60] Chandran SS, Klebanoff CA. T cell receptor-based cancer immunotherapy: emerging efficacy and pathways of resistance. Immunol Rev. 2019;290(1):127–47.
[61] Liu Y, Chen H, Hao J-H, Li Z-C, Hou T, Hao H-Q. Microarray-based transcriptional profiling of a mouse model of autoimmune hepatitis. FEBS Open Bio. 2020;10(10):2040–54.

[62] Mo W, Wang C, Li J, Chen K, Xia Y, Li S, et al. Fucosterol protects against concanavalin A-induced acute liver injury: Focus on P38 MAPK/NF-kB pathway activity. Gastroenterol Res Pract. 2018;2018:1–13.

[63] Li M, Zhao H, Wu J, Wang L, Wang J, Lv K, et al. Nobiletin protects against acute liver injury via targeting c-Jun N-terminal kinase (JNK)-induced apoptosis of hepatocytes. J Agric Food Chem. 2020;68(27):7112–20.

[64] Feng J, Niu P, Chen K, Wu L, Liu T, Xu S, et al. Salidroside mediates apoptosis and autophagy inhibition in concanavalin A-induced liver injury in mice. Exp Ther Med. 2018;15(6):4599–614.

[65] Mao Y, Wang J, Yu F, Cheng J, Li H, Guo C, et al. Ghrelin reduces liver impairment in a model of concanavalin A-induced acute hepatitis in mice. Drug Des Devel Ther. 2015;9:5385–96.

[66] Zhang H, Gong Q, Li J-H, Kong X-L, Tian L, Duan L-H, et al. CpG ODN pretreatment attenuates concanavalin A-induced hepatitis in mice. Int Immunopharmacol. 2010;10(10):79–85.

[67] Fan K, Zhang B, Yang H, Wang H, Tan M, Hou S, et al. A humanized anti-osteonectin antibody protects from Concanavalin A induced liver injury in mice. Eur J Pharmacol. 2011;657(1–3):144–51.

[68] Liu Y, Perego M, Xiao Q, He Y, Fu S, He J, et al. Lactoferrin-induced myeloid-derived suppressor cell therapy attenuates pathologic inflammatory conditions in newborn mice. J Clin Invest. 2019;129(10):4261–75.

[69] Zheng W, Du S, Tian M, Xu W, Tian Y, Li T, et al. Lepidium meyenii walp exhibits anti-inflammatory activity against con A-induced acute hepatitis. Mediators Inflamm. 2018;2018:1–11.

[70] Guo MZ, Meng M, Feng CC, Wang X, Wang CL. A novel polysaccharide obtained from Craterellus cornucopioides enhances immunomodulatory activity in immunosuppressive mice models via regulation of the TLR4-NF-kappaB pathway. Food Funct. 2019;10(8):4792–801.

[71] Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225–60.

[72] Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004;25(6):280–8.

[73] Luo Q, Ding J, Zhu L, Chen F, Xu L. Hepatoprotective effect of wedelolactone against Concanavalin A-induced liver injury in mice. Am J Chin Med. 2018;46(4):819–33.

[74] Webb GJ, Rana A, Hodgson J, Akhtar MZ, Ferguson JW, Neuberger JM, et al. Twenty-year comparative analysis of patients with autoimmune liver diseases on transplant waiting lists. Clin Gastroenterol Hepatol. 2018;16(2):278–87.

[75] Hennes EM, Zieniya M, Czaja AJ, Pares A, Dalekos GN, Krawitt EL, et al. International autoimmune Hepatitis G. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48(1):169–76.

[76] Liberali R, Mieli-Vergani G, Vergani D. Clinical significance of autoantibodies in autoimmune hepatitis. J Autoimmun. 2013;46:17–24.

[77] Christen U. The role of autoantibodies in autoimmune hepatitis type 2. Immunotherapy. 2013;5(3):247–56.

[78] Muratori P, Lalanne C, Fabbri A, Cassani F, Lenzi M, Muratori L. Type 1 and type 2 autoimmune hepatitis in adults share the same clinical phenotype. Aliment Pharmacol Ther. 2015;41(12):1281–7.

[79] Nascimento WC, Silva RP, Fernandes ES, Silva MC, Holanda GC, Santos PA, et al. Immunomodulation of liver injury by Ascaris suum extract in an experimental model of autoimmune hepatitis. Parasitol Res. 2014;113(9):3309–17.

[80] Tian X, Liu Y, Liu X, Gao S, Sun X. Glycyrrhizin acid ammonium salt alleviates Concanavalin A-induced immunological liver injury in mice through the regulation of the balance of immune cells and the inhibition of hepatocyte apoptosis. Biomed Pharmacother. 2019;120:109481.

[81] Liang M, Liwen Z, Yun Z, Yanbo D, Jianping C. The imbalance between Foxp3Tregs and Th1/Th17/Th22 cells in patients with newly diagnosed autoimmune hepatitis. J Immunol Res. 2018;2018:3753081.

[82] Miyazawa Y, Tsutsui H, Mizuhashi H, Fujiwara H, Kaneda K. Involvement of intrinsinosoidal hemostasis in the development of concanavalin A-induced hepatic injury in mice. Hepatology. 1998;27(2):497–506.

[83] Kato J, Okamoto T, Motoyama H, Uchiyama R, Kirchhofer D, Van Rooijen N, et al. Interferon-gamma-mediated tissue factor expression contributes to T-cell-mediated hepatitis through induction of hypercoagulation in mice. Hepatology. 2013;57(1):362–72.

[84] Weerasinghe SV, Moons DS, Altshuler PJ, Shah YM, Omary MB. Fibrinogen-gamma proteolysis and solubility dynamics during apoptotic mouse liver injury: heparin prevents and treats liver damage. Hepatology. 2011;53(4):1323–32.

[85] Cavada BS, Osterne VJS, Lossio CF, Pinto-Junior VR, Oliveira MV, Silva MLT, et al. One century of ConA and 40 years of ConBr research: a structural review. Int J Biol Macromol. 2015;79:901–11.

[86] Li WW, Yu JY, Xu HL, Bao JK. Concanavalin A: a potential anti-neoplastic agent targeting apoptosis, autophagy and anti-angiogenesis for cancer therapeutics. Biochem Biophys Res Commun. 2011;414(2):282–6.

[87] Sass G, Heinlein S, Agli A, Bang R, Schümann J, Tiefs G. Cytokine expression in three mouse models of experimental hepatitis. Cytokine. 2002;19(3):115–20.

[88] Ye T, Wang T, Yang X, Fan X, Wen M, Shen Y, et al. Comparison of Concanavalin A-induced murine autoimmune hepatitis models. Cell Physiol Biochem. 2018;46(3):1241–51.

[89] Liu Y, Chen H, Hao J, Li Z, Hou T, Hao H. Characterization and functional prediction of the MicroRNAs differentially expressed in a mouse model of Concanavalin A-induced autoimmune Hepatitis. Int J Med Sci. 2020;17(15):2312–27.

[90] Liu Y, Li Z, Hao J, Chen H, Hou T, Hao H. Circular RNAs associated with a mouse model of concanavalin A-induced autoimmune hepatitis: preliminary screening and comprehensive functional analysis. FEBS Open Bio. 2020;10(11):2350–62.

[91] Yang F, Lou G, Zhou X, Zheng M, He J, Chen Z. MicroRNA-223 acts as an important regulator to Kupffer cells activation at the early stage of Con A-induced acute liver failure via AIM2 signaling pathway. Cell Physiol Biochem. 2014;34(6):2137–52.

[92] Ke Q-H, Chen H-Y, He Z-L, Lv Z, Xu X-F, Qian Y-G, et al. Silencing of microRNA-375 affects immune function in mice with liver failure by upregulating astrocyte elevated gene-1
through reducing apoptosis of Kupffer cells. J Cell Biochem. 2019;120(1):253–63.

[93] Collier SP, Collins PL, Williams CL, Boothby MR, Aune TM. Influence of Tmevpg1, a long intergenic non-coding RNA, on the expression of Ifng by Th1 cells. J Immunol. 2012;189(5):2084–8.

[94] Collier SP, Henderson MA, Tossberg JT, Aune TM. Regulation of the Th1 genomic locus from Ifng through Tmevpg1 by T-bet. J Immunol. 2014;193(8):3959–65.

[95] Zhuang Y, Li Y, Li X, Xie Q, Wu M. Atg7 knockdown augments Concanavalin A-induced acute Hepatitis through an ROS-mediated p38/MAPK pathway. PLoS ONE. 2016;11(3):e0149754.

[96] Wang J, Cao X, Zhao J, Zhao H, Wei J, Li Q, et al. Critical roles of conventional dendritic cells in promoting T cell-dependent hepatitis through regulating natural killer T cells. Clin Exp Immunol. 2017;188(1):127–37.

[97] Umeda N, Endo-Umeda K, Nakashima H, Kato S, Seki S, Makishima M. Frontline science: Concanavalin A-induced acute hepatitis is attenuated in vitamin D receptor knockout mice with decreased immune cell function. J Leukoc Biol. 2019;106(4):791–801.

[98] Rani R, Kumar S, Sharma A, Mohanty SK, Donnelly B, Tiao GM, et al. Mechanisms of concanavalin A-induced cytokine synthesis by hepatic stellate cells: distinct roles of interferon regulatory factor-1 in liver injury. J Biol Chem. 2018;293(48):18466–76.

[99] He GW, Gunther C, Kremer AE, Thonn V, Amann K, Poremba C, et al. PGAM5-mediated programmed necrosis of hepatocytes drives acute liver injury. Gut. 2017;66(4):716–23.